Cargando…
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Malignant pleural mesotheliomas (MPM) are most often surgically unresectable, and they respond poorly to current chemotherapy and radiation therapy. Between 23 and 64% of malignant pleural mesothelioma have somatic inactivating mutations in the BAP1 gene. BAP1 is a homologous recombination (HR) DNA...
Autores principales: | Srinivasan, Gayathri, Sidhu, Gurjit Singh, Williamson, Elizabeth A., Jaiswal, Aruna S., Najmunnisa, Nasreen, Wilcoxen, Keith, Jones, Dennie, George, Thomas J., Hromas, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608777/ https://www.ncbi.nlm.nih.gov/pubmed/28756516 http://dx.doi.org/10.1007/s00280-017-3401-y |
Ejemplares similares
-
The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells
por: Hromas, Robert, et al.
Publicado: (2017) -
MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers
por: Srinivasan, Gayathri, et al.
Publicado: (2019) -
Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009) -
Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023) -
Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)